There are currently 582 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501
Recruiting
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Nebraska Cancer Specialists (Satellite Site), Omaha, Nebraska +2 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
Recruiting
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Urothelial Carcinoma
Register for Updates
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097
Recruiting
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping the... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/10/2025
Locations: Children's Hospital and Medical Center of Omaha, Omaha, Nebraska +1 locations
Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Register for Updates
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04181060
Recruiting
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes can... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2025
Locations: Alegent Health Immanuel Medical Center, Omaha, Nebraska +3 locations
Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224
Recruiting
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This tri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2025
Locations: Alegent Health Immanuel Medical Center, Omaha, Nebraska +3 locations
Conditions: Metastatic Bladder Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Metastatic Urothelial Carcinoma, Refractory Urothelial Carcinoma
Register for Updates
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586
Recruiting
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
05/09/2025
Locations: Children's Hospital and Medical Center of Omaha, Omaha, Nebraska +1 locations
Conditions: Primary Mediastinal Large B-Cell Lymphoma
Register for Updates
Frespaciguat INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
05/09/2025
Locations: Creighton University Clinical Research Office ( Site 0123), Omaha, Nebraska
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Register for Updates
Abbott Medical - VERITAS Study
NCT06707688
Recruiting
The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: CHI Health Creighton University Medical Center-Bergan Mercy, Omaha, Nebraska
Conditions: Atrial Fibrillation (AF), Stoke
Register for Updates
Optimizing Body Mass Index (BMI) With TCMCB07, The Paradox Trial
NCT06937177
Recruiting
This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 100 patients with newly diagnosed metastatic colorectal cancer. This study will evaluate different doses of B07 on weight, body composition and BMI in patients with sub-optimal BMIs (18 to ≤ 29 kg/m2). Treatment will begin on the same day as the start of cancer chemotherapy and continue during the first 28 days of cytotoxic therapy with a goal of preserving muscle and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Investigative Site, Omaha, Nebraska
Conditions: Cachexia; Cancer
Register for Updates
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550
Recruiting
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
05/09/2025
Locations: Research Site, Omaha, Nebraska
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794
Recruiting
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Velocity Clinical Research-Omaha, Omaha, Nebraska
Conditions: Acute Gastroenteritis, Norovirus Acute Gastroenteritis
Register for Updates
Pentoxifylline in Diabetic Kidney Disease
NCT03625648
Recruiting
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska
Conditions: Diabetic Kidney Disease
Register for Updates